ENDO PHARMA LLC

Form 4

October 17, 2005

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

OMB Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

OMB APPROVAL

response...

subject to Section 16. Form 4 or Form 5 obligations

may continue.

if no longer

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section See Instruction

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person *

2. Issuer Name and Ticker or Trading

5. Relationship of Reporting Person(s) to

Issuer

ENDO PHARMA LLC

Symbol

ENDO PHARMACEUTICALS HOLDINGS INC [ENDP]

(Check all applicable)

(Last) (First) (Middle)

(Street)

3. Date of Earliest Transaction

_X__ 10% Owner Director _ Other (specify Officer (give title

(Month/Day/Year) 320 PARK AVENUE

10/13/2005

6. Individual or Joint/Group Filing(Check

4. If Amendment, Date Original

Applicable Line)

Filed(Month/Day/Year)

X Form filed by One Reporting Person Form filed by More than One Reporting

Person

below)

NEW YORK, NY 10022

(City)	(State)	(Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned								
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactio Code (Instr. 8)	4. Securities Acquired on(A) or Disposed of (D) (Instr. 3, 4 and 5) (A) or			5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock, par value \$.01 per share	10/13/2005		Code V	Amount 5,198	(D)	Price \$ 2.42	(Instr. 3 and 4) 22,420,594	D		
Common Stock, par value \$.01 per share	10/13/2005		X	2,456	D	\$ 2.42	22,418,138	D		
Common Stock, par value \$.01 per share	10/13/2005		X	16,165	D	\$ 2.42	22,401,973	D		

Edgar Filing: ENDO PHARMA LLC - Form 4

Common Stock, par value \$.01 per share	10/13/2005	X	18,445	D	\$ 2.42	22,383,528	D
Common Stock, par value \$.01 per share	10/13/2005	X	7,141	D	\$ 2.42	22,376,387	D
Common Stock, par value \$.01 per share	10/13/2005	X	1,441	D	\$ 2.42	22,374,946	D
Common Stock, par value \$.01 per share	10/13/2005	X	750	D	\$ 3	22,374,196	D
Common Stock, par value \$.01 per share	10/13/2005	X	589	D	\$ 3	22,373,607	D
Common Stock, par value \$.01 per share	10/13/2005	X	1,141	D	\$ 3	22,372,466	D
Common Stock, par value \$.01 per share	10/13/2005	X	11,415	D	\$ 3.42	22,361,051	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (Instr.		5. Number of tiorDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		Underlying	7. Title and Amount o Underlying Securities (Instr. 3 and 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number	

								of Share
Call Option (obligation to sell)	\$ 2.42	10/13/2005	X	5,198	10/13/2005	08/26/2007	Common Stock	5,198
Call Option (obligation to sell)	\$ 2.42	10/13/2005	X	2,456	10/13/2005	08/26/2007	Common Stock	2,456
Call Option (obligation to sell)	\$ 2.42	10/13/2005	X	16,165	10/13/2005	08/26/2007	Common Stock	16,16
Call Option (obligation to sell)	\$ 2.42	10/13/2005	X	18,445	10/13/2005	08/26/2007	Common Stock	18,44
Call Option (obligation to sell)	\$ 2.42	10/13/2005	X	7,141	10/13/2005	08/26/2007	Common Stock	7,141
Call Option (obligation to sell)	\$ 2.42	10/13/2005	X	1,441	10/13/2005	08/26/2007	Common Stock	1,441
Call Option (obligation to sell)	\$ 3	10/13/2005	X	750	10/13/2005	08/26/2007	Common Stock	750
Call Option (obligation to sell)	\$ 3	10/13/2005	X	589	10/13/2005	08/26/2007	Common Stock	589
Call Option (obligation to sell)	\$ 3	10/13/2005	X	1,141	10/13/2005	08/26/2007	Common Stock	1,141
Call Option (obligation to sell)	\$ 3.42	10/13/2005	X	11,415	10/13/2005	08/26/2007	Common Stock	11,41

Reporting Owners

to sell)

Officer

Reporting Owner Name / Address	Relationships							
Reporting Owner Name / Namess	Director	10% Owner	Officer	Other				
ENDO PHARMA LLC 320 PARK AVENUE NEW YORK, NY 10022		X						
Signatures								
/s/ Jeffrey R. Black Chief Finan	icial	10/2	17/2005					

**Signature of Reporting Person Date

Reporting Owners 3

Edgar Filing: ENDO PHARMA LLC - Form 4

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.